Febuxostat Dosing for Severe Hyperuricemia

Initial Dosing Strategy

The American College of Rheumatology recommends starting febuxostat at 40 mg once daily, then titrating upward to 80 mg daily (or 120 mg daily if available outside the US) based on serum uric acid response, with the goal of achieving serum uric acid <6 mg/dL 1, 2
The starting dose should always be low to minimize the risk of precipitating acute gout flares during initial urate mobilization, as recommended by the European League Against Rheumatism 1, 3
A serum uric acid of 30 mg/dL represents severe hyperuricemia requiring aggressive urate-lowering therapy, but dose escalation should still follow a stepwise approach, according to the American College of Rheumatology 1

After 2-4 weeks, check serum uric acid levels and escalate to 80 mg daily if the target of <6 mg/dL has not been achieved, as recommended by the European League Against Rheumatism 3
The maximum FDA-approved dose in the United States is 80 mg daily, as stated by the American College of Rheumatology 4, 1
In countries outside the US where 120 mg is approved, this higher dose can be used for refractory cases that fail to reach target with 80 mg daily, according to the American College of Rheumatology 4, 1, 2

The primary target is serum uric acid <6 mg/dL (360 µmol/L), as recommended by the European League Against Rheumatism 3
For patients with severe disease burden (tophi, chronic arthropathy, frequent attacks), consider a lower target of <5 mg/dL (300 µmol/L) to facilitate faster crystal dissolution, according to the European League Against Rheumatism 3

Provide prophylaxis with colchicine 0.5-1 mg daily OR low-dose NSAIDs for at least 6 months when starting febuxostat, as recommended by the European League Against Rheumatism 3
Febuxostat does not reduce gout attacks in the first 6 months and may paradoxically increase flare frequency initially, according to the European League Against Rheumatism 5

If febuxostat at maximum dose (80 mg or 120 mg) fails to achieve serum uric acid <6 mg/dL, switch to allopurinol (if not previously tried or contraindicated), as recommended by the American College of Rheumatology 1, 2
Add a uricosuric agent (probenecid, fenofibrate, or losartan) in combination with febuxostat, according to the American College of Rheumatology 4, 1
Consider pegloticase only for severe refractory disease with tophi and poor quality of life when all oral options have failed, as recommended by the American College of Rheumatology 4, 1, 2

Discontinuing colchicine (or low‑dose NSAID) prophylaxis after 8 weeks markedly increases the risk of acute gout attacks during the first 6 months of febuxostat therapy. 6

In patients with gout, febuxostat 80 mg once daily achieves the serum urate target < 6 mg/dL in 67 % of cases, compared with 42 % for allopurinol 300 mg once daily. 6
No clinically important differences in overall adverse‑event rates are observed between febuxostat 40 mg daily and allopurinol 300 mg daily. 6

Extension data (EXCEL study) show that maintaining serum urate < 6 mg/dL reduces the incidence of acute gout attacks to ≈ 5 % after 12 months and approaches 0 % by 32 months, regardless of whether febuxostat or another urate‑lowering agent is used. 6